VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
VERAXA Biotech and Voyager Acquisition Corp (NASDAQ: VACH) have announced a definitive business combination agreement valued at a pre-money equity value of $1.3 billion. The merger will create a Nasdaq-listed biopharmaceutical company focused on next-generation cancer therapies.
The combined entity will trade under ticker VERX and have access to up to $253 million in cash held in trust. VERAXA's proprietary BiTAC platform develops novel cancer therapies, including Antibody-Drug Conjugates (ADCs) and Bispecific T-cell Engagers (TCEs). Their pipeline includes nine development programs, with VX-A901 already in Phase 1 trials for leukemia.
The transaction is expected to close in Q4 2025, subject to shareholder approval. VERAXA is also raising a crossover financing round expected to close before the business combination. The global market potential is significant, with TCE market projected to reach $112 billion by 2030 (CAGR >44%) and ADC market expected to hit $57 billion by 2030 (CAGR ~30%).
VERAXA Biotech e Voyager Acquisition Corp (NASDAQ: VACH) hanno annunciato un accordo definitivo per una fusione aziendale con una valutazione pre-money di 1,3 miliardi di dollari. La fusione darà vita a una società biofarmaceutica quotata al Nasdaq, focalizzata sulle terapie oncologiche di nuova generazione.
La società combinata sarà quotata con il ticker VERX e avrà accesso a fino a 253 milioni di dollari in contanti depositati in trust. La piattaforma proprietaria di VERAXA, BiTAC, sviluppa terapie innovative contro il cancro, tra cui coniugati anticorpo-farmaco (ADC) e bispecifici attivatori di cellule T (TCE). Il loro portafoglio comprende nove programmi di sviluppo, con VX-A901 già in fase 1 di sperimentazione per la leucemia.
La transazione è prevista per il quarto trimestre del 2025, subordinata all’approvazione degli azionisti. VERAXA sta inoltre raccogliendo fondi tramite un round di finanziamento crossover che dovrebbe chiudersi prima della fusione. Il potenziale di mercato globale è significativo, con il mercato dei TCE stimato raggiungere 112 miliardi di dollari entro il 2030 (CAGR >44%) e quello degli ADC previsto a 57 miliardi di dollari entro il 2030 (CAGR circa 30%).
VERAXA Biotech y Voyager Acquisition Corp (NASDAQ: VACH) han anunciado un acuerdo definitivo para una combinación empresarial valorada en 1.300 millones de dólares antes de la inversión. La fusión creará una compañía biofarmacéutica cotizada en Nasdaq, centrada en terapias oncológicas de próxima generación.
La entidad combinada cotizará bajo el símbolo VERX y tendrá acceso a hasta 253 millones de dólares en efectivo en fideicomiso. La plataforma propietaria de VERAXA, BiTAC, desarrolla nuevas terapias contra el cáncer, incluyendo conjugados anticuerpo-fármaco (ADC) y activadores bispecíficos de células T (TCE). Su cartera incluye nueve programas en desarrollo, con VX-A901 ya en ensayos de fase 1 para leucemia.
Se espera que la transacción se cierre en el cuarto trimestre de 2025, sujeta a la aprobación de los accionistas. VERAXA también está recaudando fondos en una ronda de financiamiento crossover que se espera cerrar antes de la combinación empresarial. El potencial del mercado global es significativo, con el mercado de TCE proyectado para alcanzar 112.000 millones de dólares para 2030 (CAGR >44%) y el mercado de ADC estimado en 57.000 millones para 2030 (CAGR aproximadamente 30%).
VERAXA Biotech와 Voyager Acquisition Corp (NASDAQ: VACH)가 13억 달러의 프리머니 기업가치로 확정된 사업 결합 계약을 발표했습니다. 이번 합병으로 차세대 암 치료제에 집중하는 나스닥 상장 생명공학 기업이 탄생합니다.
합병 법인은 VERX라는 티커로 거래되며, 신탁에 보관된 최대 2억 5,300만 달러의 현금에 접근할 수 있습니다. VERAXA의 독자적인 BiTAC 플랫폼은 항체-약물 접합체(ADC)와 이중특이성 T세포 활성화제(TCE)를 포함한 혁신적인 암 치료제를 개발합니다. 파이프라인에는 9개의 개발 프로그램이 있으며, VX-A901은 이미 백혈병 대상 1상 임상시험 중입니다.
이번 거래는 주주 승인 조건 하에 2025년 4분기에 완료될 예정입니다. VERAXA는 사업 결합 전에 마감될 예정인 크로스오버 펀딩 라운드도 진행 중입니다. 글로벌 시장 잠재력은 매우 크며, TCE 시장은 2030년까지 1,120억 달러에 달할 것으로 예상되며(CAGR 44% 이상), ADC 시장은 2030년까지 570억 달러에 이를 전망입니다(CAGR 약 30%).
VERAXA Biotech et Voyager Acquisition Corp (NASDAQ : VACH) ont annoncé un accord définitif de fusion valorisé à 1,3 milliard de dollars en capital avant investissement. Cette fusion créera une société biopharmaceutique cotée au Nasdaq, spécialisée dans les thérapies anticancéreuses de nouvelle génération.
L’entité fusionnée sera cotée sous le symbole VERX et disposera d’un accès à jusqu’à 253 millions de dollars en liquidités détenues en fiducie. La plateforme propriétaire de VERAXA, BiTAC, développe des thérapies innovantes contre le cancer, incluant des conjugués anticorps-médicament (ADC) et des activateurs bispécifiques des cellules T (TCE). Leur pipeline comprend neuf programmes de développement, avec VX-A901 déjà en phase 1 d’essais cliniques pour la leucémie.
La transaction devrait être finalisée au quatrième trimestre 2025, sous réserve de l’approbation des actionnaires. VERAXA mène également une levée de fonds crossover qui devrait se clôturer avant la fusion. Le potentiel du marché mondial est important, avec un marché des TCE projeté à 112 milliards de dollars d’ici 2030 (TCAC >44 %) et un marché des ADC attendu à 57 milliards de dollars d’ici 2030 (TCAC environ 30 %).
VERAXA Biotech und Voyager Acquisition Corp (NASDAQ: VACH) haben eine endgültige Vereinbarung zur Unternehmenszusammenführung mit einem Pre-Money-Equity-Wert von 1,3 Milliarden US-Dollar bekannt gegeben. Die Fusion wird ein an der Nasdaq gelistetes biopharmazeutisches Unternehmen schaffen, das sich auf Therapien der nächsten Generation gegen Krebs spezialisiert.
Das kombinierte Unternehmen wird unter dem Ticker VERX gehandelt und erhält Zugang zu bis zu 253 Millionen US-Dollar in Treuhandgeldern. VERAXAs proprietäre BiTAC-Plattform entwickelt neuartige Krebstherapien, darunter Antikörper-Wirkstoff-Konjugate (ADC) und bispezifische T-Zell-Engager (TCE). Die Pipeline umfasst neun Entwicklungsprogramme, wobei VX-A901 bereits in Phase-1-Studien bei Leukämie ist.
Der Abschluss der Transaktion wird für das vierte Quartal 2025 erwartet, vorbehaltlich der Zustimmung der Aktionäre. VERAXA führt zudem eine Crossover-Finanzierungsrunde durch, die vor der Unternehmenszusammenführung abgeschlossen sein soll. Das globale Markpotenzial ist erheblich, wobei der TCE-Markt bis 2030 voraussichtlich 112 Milliarden US-Dollar erreichen wird (CAGR >44%) und der ADC-Markt auf 57 Milliarden US-Dollar anwachsen soll (CAGR ca. 30%).
- Access to up to $253 million in cash held in trust
- Strong market potential with TCE market projected at $112B by 2030
- Pipeline of 9 development programs including Phase 1 asset
- Additional funding expected from crossover financing round
- 100% equity rollover from existing shareholders showing confidence
- Transaction subject to shareholder approval and closing conditions
- No immediate revenue generation from clinical-stage pipeline
- Potential redemptions could reduce available cash
- Significant competition in ADC and TCE markets
Insights
SPAC deal values VERAXA at $1.3B with potential $253M cash infusion, providing public market access for early-stage cancer therapy platform.
The announced business combination between VERAXA Biotech and Voyager Acquisition Corp represents a substantial transaction valuing VERAXA at $1.3 billion pre-money. The structure provides VERAXA shareholders with approximately 130 million ordinary shares of the combined company, with existing shareholders rolling over 100% of their equity - indicating strong confidence in the combined entity's future prospects.
Upon closing in Q4 2025, the combined company would have access to up to $253 million in cash held in trust by Voyager (pre-transaction costs and assuming no redemptions). The pro forma equity value is projected at $1.64 billion at a $10.00 share price.
VERAXA is simultaneously raising a crossover financing round expected to close before the business combination. According to management, this combined capital structure should provide sufficient funding for the next two years of operations.
This SPAC transaction provides VERAXA a path to public markets under ticker symbol "VERX" on NASDAQ, enabling capital market access to fund its oncology pipeline development. The transaction timeline is notably extended, with completion not expected until Q4 2025, suggesting a lengthy regulatory and approval process ahead.
VERAXA's BiTAC platform targets rapidly growing ADC and TCE cancer therapy markets with one Phase 1 asset and eight earlier-stage programs.
VERAXA's proprietary BiTAC (Bi-Targeted Antibody Cytotoxicity) platform represents a differentiated approach to cancer therapy through a dual-marker targeting strategy designed to improve safety and efficacy profiles in solid tumors. The company is pursuing two high-growth therapeutic modalities: bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).
Market projections position these as substantial opportunities, with the global TCE market projected to reach $112 billion by 2030 (CAGR >44%) and the ADC market expected to reach $57 billion by 2030 (CAGR ~30%).
VERAXA's pipeline comprises 9 discovery and development programs, with only one currently in clinical trials - a Phase 1 program in leukemia. This lead asset, VX-A901, is an Fc-enhanced therapeutic antibody targeting FLT3 with demonstrated anti-cancer activity.
The company's dual strategy involves both internal development and strategic partnerships, projecting three proprietary clinical-stage programs by 2029. Scientific advisors include Prof. Dr. Ralf C. Bargou, whose work contributed to developing blinatumomab, the first FDA-approved bispecific cancer therapy.
While targeting substantial markets with differentiated technology, investors should note that eight of nine pipeline programs remain in preclinical stages, representing typical development risk for early-stage biotechnology platforms.
- VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical Profiles
- Company Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026
- Transaction Values VERAXA at a Pre-money Equity Value of
$1.3 Billion - Actively Working with Existing and New VERAXA Investors to Raise a Crossover Financing Round, which is Expected to Close Ahead of the Business Combination, Alongside up to
$253 Million in Cash Held in Trust - Business Combination is Expected to be Completed in the Fourth Quarter of 2025
- A Joint Investor Presentation Providing an Overview of the Proposed Transaction can be Viewed: https://dealroadshow.com/e/VER2025
ZURICH, Switzerland, and BROOKLYN, New York, April 23, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, “Voyager” or the “SPAC”), announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement"). The proposed business combination (the "Business Combination") would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”
VERAXA Overview
VERAXA is advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. Through Bi-Targeted Antibody Cytotoxicity ("BiTAC"), a powerful and scalable proprietary technology platform that enables a highly specific dual-marker approach, the Company is accelerating a pipeline of next-generation cancer therapies that have the potential to expand the therapeutic window of current solid tumor standard of care treatments through improved safety and efficacy profiles.
The Company has recently widened the scope of its AI-enabled technology platform and is now actively pursuing two major drug modalities:
- Next-generation bispecific antibody drug conjugates, BiTAC ADCs and bsADCs, and
- Bi-specific antibodies targeting key immune cells, also called T cell engagers, or TCEs.
Both therapeutic modalities represent highly active and growing markets within the cancer therapy sector, respectively. The global TCE market is projected to reach
“VERAXA is committed to developing and delivering the next wave of safe and highly efficacious cancer therapies. Our platform technologies can be applied to empower multiple therapeutic strategies spanning next-generation antibody-drug conjugates including our BiTAC ADCs and bi-specific BiTAC immune cell engagers,” stated Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “Side effects too often limit today’s cancer therapies and prevent doctors from applying optimal dose levels. Our latest platform innovation, the BiTAC format, is designed to specifically address this issue and create first-in-class drug candidates with unprecedented safety and efficacy.”
VERAXA’s pipeline currently comprises nine discovery and development programs at various stages in development, including an active Phase 1 program in leukemia. The Company’s most advanced clinical asset, VX-A901, is a highly differentiated Fc-enhanced therapeutic antibody targeting FLT3 and has shown potent anti-cancer activity. VX-A901 has backbone therapy potential addressing different patient groups across several treatment lines and settings with a complementary Mechanism of Action to currently available treatment options. Through a two-fold approach of pursuing both internal innovation and strategic partnerships, the Company anticipates having a robust pipeline by 2029, including three proprietary development programs in the clinic and a growing portfolio of licensed assets.
VERAXA is led by an experienced team headed by Chief Executive Officer Christoph Antz, Ph.D and Chief Business Officer Heinz Schwer, Ph.D., MBA., both serial entrepreneurs and former venture capital investors. The leadership team is supported by international scientific advisors including Prof. Dr. Ralf C. Bargou, a renowned immuno-oncology expert whose scientific work has contributed to the successful development of the first FDA-approved bispecific cancer therapy with blinatumomab.
VERAXA Biotech’s majority shareholders are Xlife Sciences AG (SIX: XLS), a Swiss-based publicly listed life science incubator fund, the European Molecular Biology Laboratory ("EMBL"), and its technology transfer arm EMBLEM.
“Voyager’s mission is to identify innovative healthcare companies positioned for long-term success with strong business models and expansive total addressable markets. VERAXA exemplifies all these compelling characteristics, underscored by a steadfast commitment to bring transformative drug modalities to cancer patients through pursuing strategic global partnerships and advancing its proprietary pipeline,” stated Adeel Rouf, Chief Executive Officer and Director of Voyager Acquisition Corp. “We believe that the rapid change that ADCs and bispecific therapies have delivered and will continue to deliver to cancer therapy creates compelling opportunities for those with the vision to capitalize on them.”
“The planned NASDAQ listing of VERAXA Biotech marks a pivotal milestone for both VERAXA and Xlife Sciences and exemplifies our mission of bringing groundbreaking science from the lab to life - and to the market,” stated Oliver Baumann, Acting Chairman of the VERAXA Board and CEO of Xlife Sciences. "The access to the U.S. capital markets provided by this combination will support the realization of Veraxa's powerful technology platform and clinical assets, paving the way for potential significant value creation. We are proud to have supported VERAXA from its inception and, as one of the Company's largest shareholders, we are confident that this transaction will significantly accelerate its ability to deliver first-in-class therapies to patients worldwide."
“We believe next-generation ADCs and bispecifics will continue to revolutionize oncology, due to their significant improvement over standard of care treatments and higher probability of technical and regulatory success compared to other oncology drugs, as evidenced by multiple deals in excess of
Transaction Overview
Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately
Assuming a share price of
Upon the closing of the Business Combination, VERAXA anticipates access to approximately up to
Additionally, VERAXA is actively raising a crossover financing round from existing and new investors, which the Company expects to close prior to the completion of the Business Combination. Net proceeds from this capital raise are expected to provide VERAXA with sufficient capital for the next two years, not including various potential partnering and co-development opportunities.
The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions.
Additional information about the transaction will be provided in a Current Report on Form 8-K that will contain an investor presentation to be filed with the Securities and Exchange Commission (“SEC”) and will be available at www.sec.gov. In addition, VERAXA intends to file relevant materials with the SEC, including a registration statement on Form F-4 (the "Registration Statement") to be filed with the SEC, which will include a proxy statement/prospectus of Voyager, and will file other documents regarding the Business Combination with the SEC. This communication Is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Voyager has filed or may file with the SEC in connection with the Business Combination.
Advisors
Anne Martina Group is acting as sole M&A advisor to VERAXA. Duane Morris LLP is acting as legal counsel to VERAXA. Winston & Strawn LLP is serving as legal counsel to Voyager.
Transaction Presentation Details
A presentation providing further details on the transaction can be found here: https://dealroadshow.com/e/VER2025
About VERAXA Biotech
At VERAXA Biotech, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including BiTAC antibody-drug conjugates ("BiTAC ADCs"), bispecific T cell engagers ("BiTAC TCEs"), and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory ("EMBL"), a world-renowned institution known for pioneering life science research and cutting-edge technologies. For more information, please visit www.veraxa.com.
About Voyager Acquisition Corp.
Voyager Acquisition Corp. is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry. For more information, please visit https://www.voyageracq.com.
About Xlife Sciences AG (SIX: XLS)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch/en/home
Participants In the Solicitation
Voyager, VERAXA, and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Voyager’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of Voyager’s directors and officers in Voyager’s filings with the SEC, including, when filed with the SEC, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to VERAXA’s directors and executive officers will also be included in the proxy statement/prospectus. You may obtain free copies of these documents as described below under the heading "Additional Information and Where to Find It".
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Voyager or VERAXA, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release includes certain statements that may be considered forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements about future events or Voyager’s or VERAXA’s future financial or operating performance. For example, statements regarding VERAXA’s anticipated growth and the anticipated growth and other metrics, statements regarding the benefits of the Business Combination, and the anticipated timing of the completion of the Business Combination are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.
These forward-looking statements regarding future events and the future results of Voyager and VERAXA are based on current expectations, estimates, forecasts, and projections about the industry in which VERAXA operates, as well as the beliefs and assumptions of Voyager’s management and VERAXA’s management. These forward-looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Voyager relating to its initial public offering filed with the SEC, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Voyager; (ii) uncertainties; (iii) assumptions; and (v) other factors beyond Voyager’s or VERAXA’s control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, VERAXA’s actual results may differ materially and adversely from those expressed or implied in any forward-looking statements and Voyager and VERAXA therefore caution against relying on any of these forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Voyager and its management, VERAXA and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Voyager’s or VERAXA’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Voyager, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (v) projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, and the estimated implied enterprise value of VERAXA; (vi) VERAXA’s ability to scale and grow its business, and the advantages and expected growth of VERAXA; (vii) VERAXA’s ability to source and retain talent, the cash position of VERAXA following closing of the Business Combination; (viii) the ability to meet stock exchange listing standards in connection with, and following, the consummation of the Business Combination; (ix) the risk that the Business Combination disrupts current plans and operations of VERAXA as a result of the announcement and consummation of the Business Combination; (x) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of VERAXA to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (xi) costs related to the Business Combination; (xii) changes in applicable laws, regulations, political and economic developments; (xiii) the possibility that VERAXA may be adversely affected by other economic, business and/or competitive factors; (xiv) VERAXA’s estimates of expenses and profitability; (xv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (xvi) other risks and uncertainties set forth in the filings by Voyager with the SEC. There may be additional risks that neither Voyager nor VERAXA presently know or that Voyager and VERAXA currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Any forward-looking statements made by or on behalf of Voyager or VERAXA speak only as of the date they are made. None of Voyager or VERAXA undertakes any obligation to update any forward-looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.
Additional Information and Where to Find It
In connection with the Business Combination, Voyager and/or VERAXA intend to file relevant materials with the SEC, including the Registration Statement, which will include a proxy statement/prospectus of Voyager, and will file other documents regarding the proposed transaction with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Voyager has filed or may file with the SEC in connection with the proposed transaction. When available, the definitive proxy statement and other relevant materials for the proposed transaction will be mailed or made available to stockholders of Voyager as of a record date to be established for voting on the proposed transaction.
Before making any voting or investment decision, investors and stockholders of Voyager are urged to carefully read, when they become available, the entire registration statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Voyager, VERAXA, and the proposed transaction. Voyager’s investors and stockholders and other interested persons will also be able to obtain copies of the registration statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Voyager in connection with the Transaction, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Voyager at the address set forth below.
Contact
| VERAXA Biotech AG | Voyager Acquisition Corp. |
| Dr. Christoph Antz CEO Telephone: +49-6221-3521330 Email: antz@veraxa.com | Mr. Adeel Rouf Chief Executive Officer, and Director Email: adeel@voyageracq.com |
| For Media Mario Brkulj Valency Communications Telephone: +49 160 9352 9951 Email: mbrkulj@valencycomms.eu | For Investors Jim Polson FTI Consulting Email: Jim.Polson@FTIconsulting.com |
| Robert Stanislaro FTI Consulting Email: robert.stanislaro@fticonsulting.com |
FAQ
What is the value of the VERAXA Biotech and Voyager (VACHU) merger deal?
When will the VERAXA-Voyager (VACHU) merger close?
What is VERAXA's lead product candidate and its development stage?
How much cash will be available to VERAXA post-merger with VACHU?
What will be VERAXA's new stock symbol after merging with VACHU?
